Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | HPGD | P15428 | 3/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.48 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.48 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4243028 | 0.85 | SMN1; SMN2 (0.64) | SMN1; SMN2MAPTHPGDMAPK1CYP2C19 | |
| SCHEMBL9495103 | 0.83 | SMN1; SMN2 (0.71) | SMN1; SMN2MAPTHPGDMAPK1CYP2C19 | |
| SCHEMBL9149244 | 0.82 | SMN1; SMN2 (0.53) | SMN1; SMN2MAPTHPGDMAPK1CYP2C19 | |
| SCHEMBL4092574 | 0.78 | NOTUM (0.61) | SMN1; SMN2MAPTALOX12ALDH1A1KMT2A | |
| SCHEMBL13590001 | 0.78 | CA1 (0.63) | SMN1; SMN2MAPTHTTALDH1A1CA1 | |
| SCHEMBL11412031 | 0.77 | SMN1; SMN2 (0.64) | SMN1; SMN2MAPTHPGDMAPK1CYP2C19 | |
| SCHEMBL6579498 | 0.77 | MAPK1 (0.68) | SMN1; SMN2MAPTHPGDMAPK1CYP2C19 | |
| SCHEMBL8742796 | 0.77 | SMN1; SMN2 (0.60) | SMN1; SMN2MAPTHPGDMAPK1CYP2C19 | |
| SCHEMBL20605366 | 0.77 | NLRP3 (0.65) | SMN1; SMN2MAPTHPGDMAPK1CYP2C19 | |
| SCHEMBL9060872 | 0.77 | HPGD (0.68) | SMN1; SMN2MAPTHPGDMAPK1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120270878-A1 | INHIBITION OF P38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS | BAYER HEALTHERCARE LLC (US) | 2012-10-25 | — | — | US | disclosed |
| US-7517880-B2 | Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-04-14 | — | — | US | disclosed |
| US-20090093526-A1 | INHIBITION OF P38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS | BAYER HEALTHCARE LLC | 2009-04-09 | — | — | US | disclosed |
| US-20080269265-A1 | Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas | MILLER SCOTT | 2008-10-30 | — | — | US | disclosed |
| EP-1616865-A1 | Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas | Bayer Pharmaceuticals Corporation (US) | 2006-01-18 | — | — | EP | disclosed |
| EP-1042305-B1 | INHIBITION OF p38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS | BAYER PHARMACEUTICALS CORP (US) | 2005-06-08 | — | — | EP | disclosed |
| EP-1049664-B1 | INHIBITION OF RAF KINASE USING SYMMETRICAL AND UNSYMMETRICAL SUBSTITUTED DIPHENYL UREAS | BAYER PHARMACEUTICALS CORP (US) | 2005-03-16 | — | — | EP | disclosed |
| EP-1449834-A2 | Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas | Bayer Corporation (US) | 2004-08-25 | — | — | EP | disclosed |
| US-20040102636-A1 | Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas | BAYER CORPORATION | 2004-05-27 | — | — | US | disclosed |
| EP-1042305-A4 | INHIBITION OF p38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS | BAYER AG (US) | 2003-05-14 | — | — | EP | disclosed |
| CN-1283180-A | Inhibition of raf kinase using symmerical and unsymmerical substituted diphenyl ureas | BAYER AG (US) | 2001-02-07 | — | — | CN | disclosed |
| EP-1049664-A1 | INHIBITION OF RAF KINASE USING SYMMETRICAL AND UNSYMMETRICAL SUBSTITUTED DIPHENYL UREAS | Bayer Corporation (US) | 2000-11-08 | — | — | EP | disclosed |
| EP-1042305-A1 | INHIBITION OF p38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS | Bayer Corporation (US) | 2000-10-11 | — | — | EP | disclosed |
| WO-1999032436-A1 | INHIBITION OF RAF KINASE USING SYMMETRICAL AND UNSYMMETRICAL SUBSTITUTED DIPHENYL UREAS | BAYER CORPORATION (US) | 1999-07-01 | — | — | WO | disclosed |
| WO-1999032463-A1 | INHIBITION OF p38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS | BAYER CORPORATION (US) | 1999-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093526-A1 | INHIBITION OF P38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS | MAP2K2, MAPK1, MAP2K1 | SMN1; SMN2 3312/4885MAPT 618/4885HPGD 1118/4885 |
| US-20040102636-A1 | Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas | MAP2K2, MAPK1, MAP2K1 | SMN1; SMN2 3312/4885MAPT 618/4885HPGD 1118/4885 |
| US-20120270878-A1 | INHIBITION OF P38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS | MAP2K2, MAPK1, MAP2K1 | SMN1; SMN2 3312/4885MAPT 618/4885HPGD 1118/4885 |
| US-20080269265-A1 | Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas | BRAF, RAF1, MAP2K2 | SMN1; SMN2 3922/4885MAPT 1525/4885HPGD 3567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.